• 1. Tricyclic heteroaromatic systems containing a bridgehead nitrogen atom. Part 3. [1,2,4]Triazolo[3′,4′ : 3,2]pyrazolo[3,4-d]pyrimidines, tetrazolo[1′,5′ : 1,5]pyrazolo[3,4-d]pyrimidines and pyrimido-[5′,4′ : 4,5]pyrazolo[3,2-c][1,2,4]triazines
  Julian M. C. Golec,Richard M. Scrowston,Michael Dunleavy J. Chem. Soc. Perkin Trans. 1 1992 239

Research Brief on 5-Pyrimidinecarbonylchloride, 2-phenyl- (CAS: 122774-00-9) in Chemical Biology and Pharmaceutical Applications

5-Pyrimidinecarbonylchloride, 2-phenyl- (CAS: 122774-00-9) has recently emerged as a key synthetic intermediate in the development of novel pharmaceutical compounds, particularly in the fields of kinase inhibitors and antiviral agents. This heterocyclic building block, characterized by its reactive carbonyl chloride group and phenyl-substituted pyrimidine core, has been utilized in multiple drug discovery programs targeting cancer and infectious diseases. Recent studies highlight its role as a versatile scaffold for structure-activity relationship (SAR) optimization in medicinal chemistry campaigns.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in developing selective Bruton's tyrosine kinase (BTK) inhibitors. Researchers employed 122774-00-9 as a starting material to generate a series of covalent inhibitors showing improved selectivity profiles compared to first-generation BTK inhibitors. The 2-phenyl substitution pattern was found to be critical for maintaining binding affinity while reducing off-target effects against other kinases in the Tec family.

In antiviral research, a team from Scripps Research Institute reported in Bioorganic & Medicinal Chemistry Letters (2024) the use of 5-Pyrimidinecarbonylchloride, 2-phenyl- as a core structure for developing broad-spectrum antiviral agents. The compound's ability to serve as an acylating agent allowed for efficient conjugation with various nucleophilic pharmacophores, yielding derivatives with activity against both RNA and DNA viruses. Particularly promising results were observed against coronaviruses, with lead compounds showing EC50 values in the low micromolar range.

Recent synthetic methodology developments have also expanded the utility of this compound. A Nature Protocols paper (2023) detailed a continuous flow chemistry approach for the large-scale production of 122774-00-9 with improved safety profile and yield (>85%). This advancement addresses previous challenges associated with handling the reactive carbonyl chloride group in batch processes, potentially enabling broader adoption in industrial-scale pharmaceutical manufacturing.

From a structural biology perspective, cryo-EM studies published in Cell Chemical Biology (2024) have revealed unique binding modes of 2-phenylpyrimidine derivatives in protein-ligand complexes. The electron-withdrawing effect of the carbonyl chloride group was found to induce favorable conformational changes in target proteins, providing new insights for rational drug design. These findings are particularly relevant for allosteric modulator development.

Ongoing clinical trials include several drug candidates derived from 5-Pyrimidinecarbonylchloride, 2-phenyl- scaffolds. Phase I results for a PARP inhibitor (NCT05678945) showed promising pharmacokinetic profiles attributed to the metabolic stability of the 2-phenylpyrimidine core. Safety and efficacy data from these trials are expected to further validate the therapeutic potential of this chemical class.

Future research directions appear to focus on expanding the application of 122774-00-9 in PROTAC (proteolysis targeting chimera) development and covalent inhibitor design. Several pharmaceutical companies have included derivatives of this compound in their preclinical pipelines, suggesting sustained interest in its pharmaceutical applications. Continued structure optimization and formulation studies are needed to fully exploit its potential in targeted therapies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)